Budesonide/formoterol dry powder in asthma: An option for control as maintenance and reliever therapy

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 2, 2010, Pages 257-267

  Santus, Pierachille ^a   Giovannelli, Francesca ^a   Di Marco, Fabiano ^a   Centanni, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Asthma; Asthma control; Budesonide; Formoterol; Maintenance therapy; Reliever therapy

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; TERBUTALINE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRY POWDER; HUMAN; INHALER; LOW DRUG DOSE; MAINTENANCE THERAPY; REVIEW;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; ETHANOLAMINES; HUMANS; NEBULIZERS AND VAPORIZERS; POWDERS;

EID: 76749120905     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903494989     Document Type: Review

References (79)

1. Greening AP, Ind PW, Northfield M, et al.. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-224
2. Woolcock A, Lundback B, Ringdal N, et al.. Comparison of addition of salmeterol to invale steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-1488
3. Pauwels RA, Lofdahl CG, Postma DS, et al.. Effect of inhaled formoterol and budesonide on exacerbations of asthma: Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-1411
4. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention - updated 2008. Available from: www.ginasthma.org [Last accessed 1 September 2009]
5. Pauwels RA, Sears MR, Campbell M, et al.. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003;22:787-794
6. Palmqvist M, Arvidsson P, Beckman O, et al.. Onset of bronchodilation of budesonide/formoterol versus salmeterol/ fluticasone in single inhalers. Pulm Pharmacol Ther 2001;14:29-34
7. Bateman ED, Boushey HA, Bousquet J, et al.. Can guideline defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004;170:836-844
8. Nelson HS. Advair: combination treatment with fluticasone propionate/ salmeterol in the treatment of asthma. J Allergy Clin Immunol 2001;107:398-416
9. Markham A, Jarvis B. Inhaled salmeterol/ fluticasone propionate combination: a review of its use in persistent asthma. Drugs 2000;60:1207-1233
10. McGavin JK, Goa KL, Jarvis B. Inhaled budesonide/formoterol combination. Drugs 2001;61:71-78
11. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320:1368-1373 (Pubitemid 30261116)
12. Drury DE, Chong LK, Ghahramani P, et al.. Influence of receptor reserve on b-adrenoceptor-mediated responses in human lung mast cells. Br J Pharmacol 1998;124:711-718
13. Nials AT, Ball DI, Butchers PR, et al.. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 1994;251:127-135
14. Chong LK, Cooper E, Vardey CJ, et al.. Salmeterol inhibition of mediator release from human lung mast cells by b-adrenoceptor-dependent and independent mechanisms. Br J Pharmacol 1998;123:1009-1015
15. Connor BJ, Aikman SL, Barnes PJ. Tolerance to the non-bronchodilator effects of inhaled b2-agonists. N Engl J Med 1992;327:1204-1208
16. Connor BJ, Fuller RW, Barnes PJ. Non-bronchodilator effects of inhaled b2-agonists. Am J Respir Crit Care Med 1994;150:381-387
17. Erjefalt I, Persson CG. Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways. Am Rev Respir Dis 1991;144:788-791
18. Bolton PB, Lefevre P, McDonald DM. Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways. Am J Respir Crit Care Med 1997;155:1428-1435
19. Bowden JJ, Sulakvelidze I, McDonald DM. Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by b2-adrenergic agonist formoterol. J Appl Physiol 1994;77:397-405
20. Nichol G, Nix A, Barnes PJ, et al.. Prostaglandin F2a enhancement of capsaicin induced cough in man: modulation by b2-adrenergic and anticholinergic drugs. Thorax 1990;45:694-698
21. Barnes PJ. Scientic rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. Eur Respir J 2002;19:182-191
22. Collins S, Caron MG, Lefkowitz RJ. b-adrenergic receptors in hamster smooth muscle cells are trans- criptionally regulated by glucocorticoids. J Biol Chem 1988;263:9067-9070
23. Scott MG, Swan C, Wheatley AP, et al.. Identication of novel polymorphisms within the promoter region of the human b2-adrenergic receptor gene. Br J Pharmacol 1999;126:841-844
24. Mak JCW, Nishikawa M, Barnes PJ. Glucocorticosteroids increase b2-adrenergic receptor transcription in human lung. Am J Physiol 1995;12:L41-6
25. Mak JCW, Nishikawa M, Shirasaki H, et al.. Protective effects of a glucocorticoid on down-regulation of pulmonary b2-adrenergic receptors in vivo. J Clin Invest 1995;96:99-106
26. Nishikawa M, Mak JCW, Shirasaki H, et al.. Long term exposure to norepinephrine results in down-regulation and reduced mRNA expression of pulmonary b adrenergic receptors in guinea pigs. Am J Respir Cell Mol Biol 1994;10:91-99
27. Nishikawa M, Mak JCW, Shirasaki H, et al.. Differential down-regulation of pulmonary b1- and b2-adrenoceptor messenger RNA with prolonged in vivo infusion of isoprenaline. Eur J Pharmacol (Molecular Section) 1993;247:131-138
28. Koto H, Mak JCW, Haddad E-B, et al.. Mechanisms of impaired b-adrenergic receptor relaxation by interleukin-1b in vivo in rat. J Clin Invest 1996;98:1780-1787
29. Mak JCW, Hisada T, Salmon M, et al.. Reversal of IL-1b-induced up-regulation of G-protein-coupled receptor kinase activity by dexamethasone. Am J Respir Crit Care Med 2001;163:A228
30. Adcock IM, Stevens DA, Barnes PJ. Interactions between steroids and b2-agonists. Eur Respir J 1996;9:160-168
31. Eickelberg O, Roth M, Lorx R, et al.. Ligand-independent activation of the glucocorticoid receptor by b2-adrenergic receptor agonists in primary human lung broblasts and vascular smooth muscle cells. J Biol Chem 1999;274:1005-1010
32. McCormack PL, Lyseng-Williamson KA. Budesonide/formoterol. A review of its use as maintenance and reliever inhalation therapy in asthma. Drugs 2007;67:2407-2431
33. Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992;44:375-407
34. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007;29:587-595
35. Hvizdos KM, Jarvis B. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 2000;60:1141-1178
36. Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991;42:115-137
37. Hospenthal MAC, Peters JI. Long-acting beta2-agonists in the management of asthma exacerbations. Curr Opin Pulm Med 2005;11:69-73
38. Goldsmith DR, Keating GM. Budesonide/ formoterol: a review of its use in asthma. Drugs 2004;64:1597-1618
39. Cheer SM, Scott LJ. Formoterol: a review of its use in chronic obstructive pulmonarydisease. Am J Respir Med 2002;1:285-300
40. Remington TL, DiGiovine B. Long-acting beta-agonists: anti-inflammatory properties and synergy with corticosteroids in asthma. Curr Opin Pulm Med 2005;11:74-78
41. Overbeek SE, Mulder PG, Baelemans SM, et al.. Formoterol added to low-dose budesonide has no additional antiinflammatory effect in asthmatic patients. Chest 2005;128:1121-1127
42. Haahtela T, Tamminen K, Malmberg LP, et al.. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study. Eur Respir J 2006;28:748-755
43. Centenni S, Carlucci P, Santus P, et al.. Non-pulmonary effects induced the addition of formoterol to budesonide therapy in patients with mild or moderate persistent asthma. Respiration 2000;67:60-64
44. Martin RJ, Szefler SJ, Chinchilli VM, et al.. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002;165:1377-1383
45. Tronde A, Gillen M, Borgström L, et al.. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD. J Clin Pharmacol 2008;48:1300-1308
46. Banov CH. The role of budesonide in adults and children with mild-to-moderate persistent asthma. J Asthma 2004;41:5-17
47. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000;343:1064-1069
48. Källén B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 1999;93:392-395
49. Ericson A, Källén B. Use of drugs during pregnancy: unique Swedish registration method that can be improved. Swed Med Prod Agency 1999;1:8-11
50. Norjavaara E, Gerhardsson De Verdier M. Normal pregnancy out- comes in a population-based study including 2968 pregnant women exposed to budesonide. J Allergy Clin Immunol 2003;111:736-742
51. Berger WE. The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol 2006;97:24-33
52. Lecaillon JB, Kaiser G, Palmisano M, et al.. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of foradil dry powder inhalation via aerolizer-. Eur J Clin Pharmacol 1999;55:131-138
53. Eklund A, Tronde A, Hellberg IJ, et al.. Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. Biopharm Drug Dispos 2008;29:382-395
54. AstraZeneca UK Limited. Symbicort- 200/6 Turbohaler-: summary of product characteristics. Available from: http://emc.medicines.org.uk [Last accessed 1 September 2009]
55. Cazzola M, Santus P, Di Marco F, et al.. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm Pharmacol Ther 2004;17:121-125
56. BTS/SIGN. National guidelines on management of asthma. Thorax 2003;58(Suppl 1):i1-i83
57. Bousquet J, Boulet LP, Peters MJ, et al.. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/ fluticasone. Respir Med 2007;101:2437-2446
58. Kuna P, Peters MJ, Manjra AI, et al.. Effect budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61:725-736 (Pubitemid 46587876)
59. O'Byrne PM, Bisgaard H, Godard PP, et al.. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-136
60. Rabe KF, Atienza T, Magyar P, et al.. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006;368:744-753
61. Vogelmeier C, D'Urzo A, Pauwels R, et al.. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005;26:819-828
62. Pavord ID, Jeffery PK, Qui Y, et al.. Airway inammation in patients with asthma with high-xed or low-xed plus as-needed budesonide/formoterol. J Allergy Clin Immunol 2009;123:1083-1089
63. Sears MR, Boulet LP, Laviolette M, et al.. Budesonide/formoterol maintenance and reliever therapy: impact on air way inflammation in asthma. Eur Respir J 2008;31:982-989
64. Wang K, Liu CT, Wu YH, et al.. Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within air way remodelling in asthma. Adv Ther 2008;25:342-354
65. Nelson HS, Weiss ST, Bleecker ER, et al.. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26
66. Humbert M, Andersson TLG, Buhl R. Budesonide and formoterol for maintenance and reliever therapy in the management of moderate to severe asthma. Allergy 2008;63:1567-1580
67. Rabe KF, Pizzichini E, Stallberg B, et al.. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma. A randomized, double-blind trial. Chest 2006;129:246-256
68. Suissa S, Dell'Aniello S, Ernst P. Effectiveness of combination therapy in asthma: an observational study. Pulm Pharnmacol Ther 2009;22:194-198
69. Price D, Wirén A, Kuna P. Cost-effectiveness of budesonide/ formoterol for maintenance and reliever asthma therapy. Allergy 2007;62:1189-1198 (Pubitemid 47374022)
70. Hussain S. Way forward is not obvious at asthma crossroads. BMJ . 2007;335:577
71. Demoly P, Louis R, Søes-Petersen U, et al.. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir Med 2009;103:1623-1632
72. The Cochrane Library. Available from: www3.interscience.wilwy.com/cgi- bin/ mrwhome/106568753/HOME
73. Lasserson TJ, Cates CJ, Ferrara G, et al.. Combination fluticasone and salmeterol versusxed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev 2008;1:CD004106, doi: 10.1002/14651858.CD004106.pub3
74. Cates CJ, Lasserson TJ. Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. Cochrane Database Syst Rev 2009;1:CD007085, doi: 10.1002/14651858.CD007085.pub2
75. Cates CJ, Lasserson TJ. Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev 2009;2:CD007313, doi: 10.1002/14651858.CD007313.pub2
76. O'Byrne. How much is too much? The treatment of mild asthma. Eur Respir J 2007;30:403-406
77. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073-1087
78. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368:804-813
79. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneus disease. Lancet 2008;372:1107-1119